Selpercatinib与Pralsetinib治疗相关肠淋巴管扩张症的系统分析
该回顾性分析纳入113例接受selpercatinib或pralsetinib治疗的RET变异肺癌患者,系统评估肠淋巴管扩张症(IL)。33例(29%)出现IL相关影像学表现,1年、3年、5年累积发生率分别为11%、27%、31%;既往免疫检查点抑制剂暴露与IL风险相关(HR 3.02)。多数病例经剂量调整或停药后影像学及临床改善。
要点
- 长期使用selpercatinib或pralsetinib需警惕肠淋巴管扩张症,累积发生率随用药时间增加。
- 既往免疫检查点抑制剂暴露者IL风险升高(HR 3.02,95%CI 1.53-5.96,p=0.001)。
- 多数IL经剂量调整或停药后改善,仅少数需永久停药。
核心结论
- Selpercatinib或pralsetinib治疗可导致药物性肠淋巴管扩张症,发生率随用药时间延长而增加。
- 多数病例不导致治疗终止,剂量调整或停药后影像学及临床可改善。
研究设计与样本
- 回顾性分析纳入113例接受selpercatinib或pralsetinib治疗的RET变异肺癌患者。
- IL分为可能(影像学)、很可能(影像学+临床)、确诊(影像学+临床+内镜或病理)三级。
主要发现
- 113例中33例(29%)出现IL相关影像学表现。
- IL累积发生率:1年11%(95%CI 6%-18%),3年27%(95%CI 19%-36%),5年31%(95%CI 22%-41%)。
- 既往免疫检查点抑制剂暴露与IL风险相关(HR 3.02,95%CI 1.53-5.96,p=0.001)。
- IL相关影像学表现者中,可能、很可能、确诊分别占25%、60%、15%。
- 从SRI起始至影像学发现的中位时间为15个月,病变累及回肠和十二指肠者分别占67%和24%。
临床怎么用
- 对长期接受selpercatinib或pralsetinib治疗的患者应进行系列监测,警惕肠淋巴管扩张症。
- 出现IL相关表现时,可考虑剂量调整或停药,多数患者可改善且无需永久终止治疗。
局限性
- 回顾性分析设计。
- 单中心或有限样本量(113例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Selective RET inhibitors (SRIs) have durable activity in RET fusion-positive lung cancers. Insidious side effects may emerge with long-term use. This is the first systematic analysis of intestinal lymphangiectasia (IL), an underrecognized disorder characterized by dilated intestinal lacteals and potential lymph leakage, in this population. METHODS: Patients with RET-altered lung cancers treated with selpercatinib or pralsetinib were eligible for this retrospective analysis. IL was classified as possible (radiologic findings), probable (radiologic and clinical findings), and definite (radiologic, clinical, and endoscopic or pathologic findings). RESULTS: Of 113 patients, 33 (29%) had IL-associated radiologic findings. Cumulative incidence at 1, 3, and 5 years was 11% (95% confidence interval [CI], 6%-18%), 27% (95% CI, 19%-36%), and 31% (95% CI: 22%-41%), respectively. Prior immune checkpoint inhibitor exposure was associated with IL risk (hazard ratio, 3.02; 95% CI: 1.53-5.96; p = 0.001). Among patients with IL-associated findings, IL was classified as possible, probable, and definite in 25%, 60%, and 15%, respectively. Median time from SRI initiation to radiologic findings (involving the ileum and duodenum in 67% and 24% of patients with IL, respectively) was 15 months. Radiologic findings were associated with additional clinical findings (e.g., gastrointestinal symptoms, hypoalbuminemia, hypocalcemia, third spacing) in 76% of patients. All patients with assessable endoscopic biopsies had mild lacteal dilatation. IL improved radiologically and clinically in 64% of patients after SRI dose reduction or discontinuation. CONCLUSION: Drug-induced IL occurs with selpercatinib or pralsetinib treatment. The frequency increases with longer drug exposure. Serial monitoring is essential and when necessary, dose modification. Most cases do not lead to treatment discontinuation.
引用
- Rubio-Perez J, Daher S, Lin ST, et al. Brief Report: Intestinal Lymphangiectasia With Selpercatinib and Pralsetinib Treatment. J Thorac Oncol. 2026. PMID: 41933582. doi:10.1016/j.jtho.2026.103704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。